TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06518694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Βeta-Blockers discontinued (with tapering)
Description: The experimental group will undergo discontinuation of their beta-blockers treatment during the study period.~The tapering of beta-blocker will start on the day after randomisation and is based on a reduction by half-dose every 48 hours (1/2 maximally recommended dose for 48 hours, then ¼ maximally recommended dose for 48 hours) until reaching the minimal recommended dosage (1/8 maximally recommended dose) for 48 hours before complete interruption of treatment. Consequently, the tapering will not be needed in patients already receiving the minimal recommended dosage (i.e., 1/8 dose) at inclusion, and these patients will be instructed to stop taking beta-blockers the day after randomisation.
Study: NCT04685473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-1101 (Tosylate)
Description: T-1101 (Tosylate) Capsule
Study: NCT03648645

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self measurement of blood pressure
Description: Patients will perform the measurement of blood pressure at home, on a daily basis, in complying with the rule of 3 stated by the Haute Autorité de Santé (French Health Authority) : i.e. 3 consecutive measurements in the morning and in the evening, after a period of rest Measurements are performed using a blood pressure monitor Bluetooth-connected. If a threshold value is exceeded (and depending on the alert), a consultation will be scheduled (unexpected consultation) and notified to the patient.
Study: NCT06091423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOX combined with Fruquintinib and Sintilimab
Description: XELOX:Capecitabine：800mg/m2, po, bid, d1-14。Oxaliplatin：130mg/m2，ivgtt 2-6h，d1，q3w; Fruquintinib: 5 mg/d，qd po，d1-14，q3w; Sintilimab: 200mg d1, q3w
Study: NCT05157685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin Oral Tablet
Description: Treatment assigned by randomization will be prescribed immediately. The active or placebo will be dispensed by the centre's pharmacy. Treatment will be taken in the morning or evening for 3 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment assigned by randomization will be prescribed immediately. The active or placebo will be dispensed by the centre's pharmacy. Treatment will be taken in the morning or evening for 3 months.
Study: NCT04957979

Intervention type: OTHER
Intervention: Nursing/Medical Model of Care Coordination
Description: No social worker on the clinic's care coordination team.~Services provided:~* Coordinated medical care for patients~* Patient education~* Assistance in developing care plan~* Support for patient self-management~* Referrals for continuing care~* Referral to community resources~* Referral to mental health services if needed or requested~* Referral to interventional counseling for behavioral health issues

Intervention type: OTHER
Intervention: Medical/Social Model of Care Coordination
Description: Social worker is part of the clinic's care coordination team.~* Need not be licensed as a social worker~* Must have time dedicated to care coordination for a specific clinic or clinics~* Must interact with individual patients to provide them with services~* Must interact with individual clinicians about their individual patients in care coordination~Services provided:~* Coordinated medical care for patients~* Patient education~* Assistance in developing care plan~* Support for patient self-management~* Assistance with referrals for continuing care~* Assessment and plan to address social and resource needs including housing, transportation or financial needs; Assist patient in locating and obtaining needed community resources~* Assistance with identifying and addressing psychological/emotional issues and referrals as needed~* Interventional counseling for behavioral health issues or referrals to interventional counseling, depending on licensure
Study: NCT06076330

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20% Albumin
Description: S. albumin \> 3 g/dl: 20g of 20% iv albumin @10-15 ml/hr S. albumin \< 3 g/dl: 40g of 20% iv albumin @10-15 ml/hr

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 5% Albumin
Description: 5% albumin at an initial bolus of 5ml/kg iv over 15-30 mins followed by 50ml/hr maintenance dose In case of failure to attain a sustained MAP \>65 mmHg, Fluid boluses will be administered guided by lung ultrasound and IVC.
Study: NCT06097143

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flowable Giomer
Description: Pre-reacted Glass Ionomer (PRG) filler is added to resin to create giomer, a dental adhesive material. Fluoride release and recharge, acid resistance, an anti-plaque effect, dentin remineralization, and acid buffering capacity are some of the benefits of giomer.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flowable Nano-filled composite with S-PRG barrier coat
Description: Flowable composites are claimed to have a higher wetting ability of the tooth surface and thus ensure penetration into all surface irregularities in layers of minimal thickness. As a result of the higher amount of filler particles, it is noted that flowable composites have less porosity than conventional resin-based sealants. Moreover, flowable composite materials have better mechanical properties which lead to increased durability and longevity of the restoration.~The PRG Barrier Coat is a resinous coating substance that shields the enamel surface from demineralization brought on by acidic attack. Near the coated surface, S PRG filler ions in PRG Barrier Coat have been found to have an acid-neutralizing effect. F and Sr released by PRG Barrier Coat can be effectively absorbed by the tooth substrate to prevent demineralization thus hindering the progression of caries.
Study: NCT06076330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plasmalyte
Description: Plamalyte will be given at an initial bolus of 15-20 ml/kg over 15-30 mins followed by 100ml/hr maintenance
Study: NCT05015361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam Tosilate
Description: Treatment group A: Remimazolam Tosilate; high dose Treatment group B: Remimazolam Tosilate; low dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol Injection.
Description: Treatment group C: Propofol Injection.
Study: NCT06077981

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Submucous Endoscopic Dissection with hydroxyethylamide
Description: The resection will be performed in three stages using hydroxyethylamide : delimitation, incision and dissection. Initially we will inject the hydroxyethylamide and examine the delimitation of the lesion. With Knife itself, using soft or Forced coagulation current, we will circumvent the limits of the lesion with punctual coagulations 5 mm away from it.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Submucous Endoscopic Dissection with Hyaluronic acid (TS-905 Blue Eye)
Description: The resection will be performed in three stages using Hyaluronic acid (TS-905 Blue Eye) : delimitation, incision and dissection. Initially we will inject the Blue-Eyed and examine the delimitation of the lesion. With Knife itself, using soft or Forced coagulation current, we will circumvent the limits of the lesion with punctual coagulations 5 mm away from it.
Study: NCT06097143

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flowable Nano-filled composite
Description: Flowable composites are claimed to have a higher wetting ability of the tooth surface and thus ensure penetration into all surface irregularities in layers of minimal thickness. As a result of the higher amount of filler particles, it is noted that flowable composites have less porosity than conventional resin-based sealants. Moreover, flowable composite materials have better mechanical properties which lead to increased durability and longevity of the restoration.
Study: NCT05041582

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: tDCS
Description: dual tDCS with ipsilesional primary motor cortex (M1) anodal stimulation and contralesional M1 cathodal stimulation, 2 weeks after SSRI treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram
Description: total 3 months, since 2-4 weeks after stroke

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Citalopram
Description: total 3 months, since 2-4 weeks after stroke

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: hospitalized rehabilitation, 3 hours daily

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Rehabilitation
Description: hospitalized rehabilitation, 3 hours daily

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Rehabilitation
Description: hospitalized rehabilitation, 3 hours daily

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Rehabilitation
Description: hospitalized rehabilitation, 3 hours daily
Study: NCT05039593

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chlorhexidine
Description: The population of the research is the patients hospitalized in the Internal Medicine intensive care unit of Aydın Adnan Menderes University Practice and Research Hospital between 01.06.2021 and 01.06.2022, and the sample is; Patients who are older than 18 years of age, who are in the first 24 hours of mechanical ventilation, who are 18 years of age and older, and whose relatives have consented.Oral care of the patients will be done with 0.12% chlorhexidine solution, and the frequency of oral care will be in three groups. Oral care will be done twice a day for the patients in the first group, 3 times a day for the patients in the second group, and 4 times a day for the patients in the third group. Oral care of the patients will be applied according to the guide used in the training given to the nurses.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chlorhexidine
Description: The population of the research is the patients hospitalized in the Internal Medicine intensive care unit of Aydın Adnan Menderes University Practice and Research Hospital between 01.06.2021 and 01.06.2022, and the sample is; Patients who are older than 18 years of age, who are in the first 24 hours of mechanical ventilation, who are 18 years of age and older, and whose relatives have consented.Oral care of the patients will be done with 0.12% chlorhexidine solution, and the frequency of oral care will be in three groups. Oral care will be done twice a day for the patients in the first group, 3 times a day for the patients in the second group, and 4 times a day for the patients in the third group. Oral care of the patients will be applied according to the guide used in the training given to the nurses.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chlorhexidine
Description: The population of the research is the patients hospitalized in the Internal Medicine intensive care unit of Aydın Adnan Menderes University Practice and Research Hospital between 01.06.2021 and 01.06.2022, and the sample is; Patients who are older than 18 years of age, who are in the first 24 hours of mechanical ventilation, who are 18 years of age and older, and whose relatives have consented.Oral care of the patients will be done with 0.12% chlorhexidine solution, and the frequency of oral care will be in three groups. Oral care will be done twice a day for the patients in the first group, 3 times a day for the patients in the second group, and 4 times a day for the patients in the third group. Oral care of the patients will be applied according to the guide used in the training given to the nurses.
Study: NCT06331845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m2 on Days 1 and 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: a total of 80-100 mg/m2 for d1-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel protein-bound
Description: 260 mg/m2 on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: a dose of 1-1.25 g/m2 twice daily in in 2 weeks for one cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200 mg on Day 1
Study: NCT05441306

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Personal Health Library (PerHL) + MyChart
Description: Participants randomized to the PerHL arm will have access to PerHL + the standard of care patient portal (Epic®MyChart).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Epic®MyChart
Description: Participants randomized to the control arm will receive the standard of care patient portal (Epic®MyChart).
Study: NCT06127537

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Intervention Group
Description: The therapeutic group factors that are worked on in the group session with a psychologist are:~* Altruism.~* Cohesion: feeling of belonging and acceptance in a group.~* Universality: identification with the feelings, ideas or problems of the other group members.~* Interpersonal-internalisation learning: the patient understands himself/herself by sharing his/her experience with the group.~* Interpersonal-externalisation learning: the group offers the patient the possibility to express his own experience and to change his attitudes towards others.~* Counselling.~* Identification: assumption of behavioural patterns of other members as one's own.~* Reactualisation of the family experience.~* Understanding of one's own internal motivations.~* Reciprocal stimulation: the improvement of other members encourages them to solve or approach their problems in a more favourable way.~* Existential factors: empowerment of the individual.
Study: NCT06024733

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sevoflurane
Description: patient recieve propofol for induction and sevoflurane for maintenance

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Target Controlled Infusion
Description: target controlled infusion of propofol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Target Controlled Infusion and lidocaine
Description: patients will receive total intravenous anesthesia with propofol Target Controlled Infusion. At the induction of anesthesia, the patients will receive a bolus of lidocaine 1% 1.5 mg/kg and a continuous infusion of lidocaine 1% 2 mg/kg/h will be associated throughout the procedure.
Study: NCT05983887

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Climbing
Description: The protocol consists of using an in-door climbing wall as an complementary therapeutic intervention model.
Study: NCT06072430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VBI-S
Description: VBI-S is made of small particles of specific lipids called micelles and liposomes for the treatment of hypotension.
Study: NCT05386628

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional physiotherapy
Description: A basic physiotherapy program consisting of shoulder exercises will be applied to the participants.~content of the physiotherapy program~* Shoulder passive/active abduction, flexion, internal and external rotation exercises~* Posture exercises~* Neck stretching exercises~* Pectoralis major stretching exercises~* Shoulder capsule stretching exercises~* Scapular Mobilization exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional physiotherapy
Description: A basic physiotherapy program consisting of shoulder exercises will be applied to the participants.~content of the physiotherapy program~* Shoulder passive/active abduction, flexion, internal and external rotation exercises~* Posture exercises~* Neck stretching exercises~* Pectoralis major stretching exercises~* Shoulder capsule stretching exercises~* Scapular Mobilization exercises
Study: NCT06283251

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PediRISE Resource Program
Description: A centrally administered, income-poverty targeted intervention that includes twice-monthly direct provision of unrestricted cash transfers along with benefits counseling to mitigate the risk of loss of means-tested benefits. Funds will be dispersed to families via provided debit card or through personal banking, PayPal, or Venmo.
Study: NCT05013528

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bal-A-Vis-X training
Description: Bal-A-Vis-X training Performed thrice a week for 10 minutes after baseline assessment Standard Physical therapy treatment along with following exercises.~1. ball Rectangle~2. ball rectangle and 2 ball drop/pass/catch two-foot jumping forward, tandem walking on ground and tandem walking on the balance beam. .

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bal-A-Vis-X training
Description: Bal-A-Vis-X training Performed thrice a week for 10 minutes after baseline assessment Standard Physical therapy treatment along with following exercises.~1. ball Rectangle~2. ball rectangle and 2 ball drop/pass/catch two-foot jumping forward, tandem walking on ground and tandem walking on the balance beam. .

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Training Group
Description: Aerobic training group performed exercises thrice a week for 10 minutes after baseline assessment.~Standard Physical therapy treatment along with aerobic training as Running is performed

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Training Group
Description: Aerobic training group performed exercises thrice a week for 10 minutes after baseline assessment.~Standard Physical therapy treatment along with aerobic training as Running is performed
Study: NCT04698408

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high-protein, carbohydrate-reduced diet
Description: the high-protein, carbohydrate-reduced diet will consist of 1.2-1.4 g/kg/d protein, 26-20en% carbohydrates and +/- 50en% fatty acids, with mainly unsaturated fatty acids. This diet consist of mainly unprocessed, fresh nutrient-dense food-products. Ultra-processed foods and alcoholic beverages will be totally avoided. Salt consumption will not exceed 5-6 g/d. The diet is ad libitum and caloric restriction will not be applied. The diet will be followed for 6 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dutch Nutritional Guidelines
Description: the diet according to the Dutch Nutritional Guidelines will consist of a protein intake of 0.8-1.0 g/kg/d and 50-60en% carbohydrates, and +/-30en% fatty acids, with restriction of saturated fatty acids \<10en%. This diet consist of mainly unprocessed, fresh nutrient-dense food-products. Ultra-processed foods and alcoholic beverages will be totally avoided. Salt consumption will not exceed 5-6 g/d. The diet is ad libitum and caloric restriction will not be applied. The diet will be followed for 6 weeks.
Study: NCT05126095

Intervention type: RADIATION
Intervention: Radical radiotherapy
Description: Intensity-modulated radiation therapy (IMRT)
Study: NCT05010681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab will be administered at 200 mg i.v. every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib will be administered (bodyweight ≥ 60 kg, 12 mg; \< 60 kg, 8 mg) orally daily every 3 weeks until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent.
Study: NCT05386628

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional physiotherapy
Description: A basic physiotherapy program consisting of shoulder exercises will be applied to the participants.~content of the physiotherapy program~* Shoulder passive/active abduction, flexion, internal and external rotation exercises~* Posture exercises~* Neck stretching exercises~* Pectoralis major stretching exercises~* Shoulder capsule stretching exercises~* Scapular Mobilization exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional physiotherapy
Description: A basic physiotherapy program consisting of shoulder exercises will be applied to the participants.~content of the physiotherapy program~* Shoulder passive/active abduction, flexion, internal and external rotation exercises~* Posture exercises~* Neck stretching exercises~* Pectoralis major stretching exercises~* Shoulder capsule stretching exercises~* Scapular Mobilization exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual lymphatic drainage
Description: manual lymph drainage is a manual technique that is applied to the lymphatic system with a pressure of 40-50 mmHg and increases the working speed of lymphatic nodules/collectors. Manual lymph drainage will be made to the anterior axillar-axillar, posterior axillar-axillar and axilla-inguinal anastomosis collectors and the arm region (up to the elbow) lymph collectors.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual lymphatic drainage
Description: manual lymph drainage is a manual technique that is applied to the lymphatic system with a pressure of 40-50 mmHg and increases the working speed of lymphatic nodules/collectors. Manual lymph drainage will be made to the anterior axillar-axillar, posterior axillar-axillar and axilla-inguinal anastomosis collectors and the arm region (up to the elbow) lymph collectors.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial relasing
Description: it will be done with the thumb or 3rd finger from the acu points of the superficial arm-anterior myofascial chain. 6-8 seconds with thumb to these points. pressure will be applied and vibration will be given clockwise.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial relasing
Description: it will be done with the thumb or 3rd finger from the acu points of the superficial arm-anterior myofascial chain. 6-8 seconds with thumb to these points. pressure will be applied and vibration will be given clockwise.
Study: NCT04862195

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Attune™
Description: Software as a medical device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cerena™
Description: Software as a medical device
Study: NCT06260527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARTS-011
Description: Single ascending dose (SAD): 3mg, 10mg, 20mg, 40mg, and 60mg. Multiple ascending dose (MAD): 10mg QD, 20mg QD, and 40mg QD X 7 days. Food effect study: single dose of ARTS-011 under the fasting and high-fat meal.
Study: NCT05252520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-77474462
Description: JNJ-77474462 will be administered subcutaneously.